Press Releases

Date Title  
Toggle Summary Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
STOUGHTON, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut , M.D., as the company’s first Chief Medical
Toggle Summary Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in April: The H.C.
Toggle Summary Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
Xtampza ® ER Prescriptions Grew 233% in 2018 Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full Year Cash and Cash Equivalents were $146.6 million as of December 31, 2018 , exceeding year-end cash guidance of $145.0 million Conference call scheduled for
Toggle Summary Collegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, February 27, 2019 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and
Toggle Summary Collegium Provides Full-Year 2019 Financial Guidance
– Xtampza ER Revenue Expected in the Range of $95 Million to $105 Million – Nucynta Franchise Revenue Expected in the Range of $200 Million to $210 Million – Total Operating Expenses Expected in the Range of $125 Million to $135 Million STOUGHTON, Mass. , Jan.